BR112018072579B1 - Composto fenólico, composição farmacêutica, combinação do composto de fórmula i, e, usos de composto de fórmula i e de combinação - Google Patents

Composto fenólico, composição farmacêutica, combinação do composto de fórmula i, e, usos de composto de fórmula i e de combinação Download PDF

Info

Publication number
BR112018072579B1
BR112018072579B1 BR112018072579-0A BR112018072579A BR112018072579B1 BR 112018072579 B1 BR112018072579 B1 BR 112018072579B1 BR 112018072579 A BR112018072579 A BR 112018072579A BR 112018072579 B1 BR112018072579 B1 BR 112018072579B1
Authority
BR
Brazil
Prior art keywords
fact
compound
disease
combination
formula
Prior art date
Application number
BR112018072579-0A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112018072579A2 (pt
Inventor
Estael Ochoa Rodríguez
Yamila Verdecia Reyes
Yanier Nuñez Figueredo
Jeney RAMÍREZ SÁNCHEZ
Maylin WONG GUERRA
Luis Arturo Fonseca Fonseca
Gilberto Lázaro Pardo Andreu
Claudia Amanda Canaán-Haden Navarro
Abel MONDELO RODRÍGUEZ
Pedro Gilberto Bárzaga Fernández
Nicté GONZÁLEZ ALFONSO
René DELGADO HERNÁNDEZ
Alejandro Saúl Padrón Yaquis
Original Assignee
Universidad De La Habana
Centro de Investigación Y Desarrollo de Medicamentos CIDEM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universidad De La Habana, Centro de Investigación Y Desarrollo de Medicamentos CIDEM filed Critical Universidad De La Habana
Publication of BR112018072579A2 publication Critical patent/BR112018072579A2/pt
Publication of BR112018072579B1 publication Critical patent/BR112018072579B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
    • C07D319/06—1,3-Dioxanes; Hydrogenated 1,3-dioxanes not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
BR112018072579-0A 2016-05-04 2017-05-03 Composto fenólico, composição farmacêutica, combinação do composto de fórmula i, e, usos de composto de fórmula i e de combinação BR112018072579B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CU2016-0059 2016-05-04
CU2016000059A CU24576B1 (es) 2016-05-04 2016-05-04 Compuesto fenólico y combinación del mismo con una benzodiazepina fusionada a 1,4-dihidropiridina para el tratamiento de afecciones del sistema nervioso central y vascular
PCT/CU2017/050003 WO2017190714A1 (es) 2016-05-04 2017-05-03 Compuesto fenólico y combinación del mismo con una benzodiazepina fusionada a 1,4-dihidropiridina para el tratamiento de afecciones del sistema nervioso central y vascular

Publications (2)

Publication Number Publication Date
BR112018072579A2 BR112018072579A2 (pt) 2019-02-19
BR112018072579B1 true BR112018072579B1 (pt) 2024-02-20

Family

ID=60202803

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018072579-0A BR112018072579B1 (pt) 2016-05-04 2017-05-03 Composto fenólico, composição farmacêutica, combinação do composto de fórmula i, e, usos de composto de fórmula i e de combinação

Country Status (19)

Country Link
US (1) US10722491B2 (enExample)
EP (1) EP3453704B1 (enExample)
JP (1) JP6997995B2 (enExample)
KR (1) KR102416478B1 (enExample)
CN (1) CN109476627B (enExample)
AR (1) AR108370A1 (enExample)
AU (1) AU2017259749C1 (enExample)
BR (1) BR112018072579B1 (enExample)
CA (1) CA3023073C (enExample)
CL (1) CL2018003114A1 (enExample)
CO (1) CO2018011927A2 (enExample)
CU (1) CU24576B1 (enExample)
EA (1) EA037951B1 (enExample)
ES (1) ES2878579T3 (enExample)
MX (1) MX384967B (enExample)
PH (1) PH12018502327A1 (enExample)
SG (1) SG11201809843SA (enExample)
WO (1) WO2017190714A1 (enExample)
ZA (1) ZA201808161B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU20160058A7 (es) 2016-05-04 2017-12-08 Centro De Investigación Y Desarrollo De Medicamentos (Cidem) Organizacion Superior De Desarrollo Emp Derivado de benzodiazepina con actividad sobre el sistema nervioso central y vascular
JP2022504852A (ja) * 2018-10-16 2022-01-13 サバン ベンチャーズ プロプライアタリー リミテッド 医療機器の洗浄のための装置および方法
EP4082548A2 (en) * 2019-12-26 2022-11-02 Centro de Investigación y Desarrollo de Medicamentos CIDEM Use of a benzodiazepine derivative and method of treatment of traumatic brain injury
CU20190114A7 (es) 2019-12-26 2021-08-06 Centro De Investig Y Desarrollo De Medicamentos Cidem Combinación para simultáneamente incrementar la eficacia analgésica de la morfina y reducir su dependencia física

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5281714A (en) 1990-08-16 1994-01-25 American Home Products Corporation N,N',N'-trisubstituted-5-bisaminomethylene-1,3-dioxane-4,6-dione inhibitors of acyl-CoA: cholesterol-acyl transferase
MX9204939A (es) 1991-09-06 1993-03-01 American Home Prod Inhibidores 5-bis-aminometilen-1,3-dioxan-4,6-diona n,n',n'-trisubstituidas, de la acil coenzima a: colesterol-aciltransferasa.
ATE122671T1 (de) 1992-07-17 1995-06-15 Biogal Gyogyszergyar Verfahren zur herstellung von 1,3-dioxan-4,6- dionderivaten.
JPH11180975A (ja) 1997-10-13 1999-07-06 Chemiprokasei Kaisha Ltd アミノメチレンジオキサン誘導体、その製造方法および用途
EP1737809B1 (en) 2004-02-27 2013-09-18 Amgen, Inc Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders
JP2007063444A (ja) * 2005-08-31 2007-03-15 Tdk Corp 錯化合物及びこれを用いた光記録媒体

Also Published As

Publication number Publication date
CU24576B1 (es) 2022-02-04
JP2019516791A (ja) 2019-06-20
KR20210025138A (ko) 2021-03-09
AU2017259749A1 (en) 2018-12-20
EA037951B1 (ru) 2021-06-11
CL2018003114A1 (es) 2019-06-14
CA3023073C (en) 2022-08-30
EA201892462A1 (ru) 2019-07-31
EP3453704A1 (en) 2019-03-13
CO2018011927A2 (es) 2019-02-08
US10722491B2 (en) 2020-07-28
ES2878579T3 (es) 2021-11-19
CU20160059A7 (es) 2017-12-08
AU2017259749B2 (en) 2021-08-19
MX384967B (es) 2025-03-14
WO2017190714A1 (es) 2017-11-09
MX2018013422A (es) 2019-08-16
CN109476627B (zh) 2021-06-15
JP6997995B2 (ja) 2022-02-04
BR112018072579A2 (pt) 2019-02-19
AR108370A1 (es) 2018-08-15
CN109476627A (zh) 2019-03-15
PH12018502327A1 (en) 2019-09-02
CA3023073A1 (en) 2017-11-09
EP3453704B1 (en) 2021-06-16
ZA201808161B (en) 2021-10-27
AU2017259749C1 (en) 2021-12-02
US20190133996A1 (en) 2019-05-09
SG11201809843SA (en) 2018-12-28
KR102416478B1 (ko) 2022-07-04

Similar Documents

Publication Publication Date Title
CN103086908B (zh) 一类n-苄基苯胺衍生物及其用途
CN114787200A (zh) 用亲水性β-环糊精衍生物及其组合物形成包合配合物的方法
JP2010535158A (ja) Ｓ−アリルシステインまたはそのアナローグの使用およびそれらの医薬組成物
KR20190046895A (ko) 신경퇴행성 질환의 치료를 위한 니코틴아미드 리보사이드 및 프테로스틸렌 조성물 및 방법
AU2017259749B2 (en) Phenol compound and combination of same with a benzodiazepine fused to 1,4-dihydropyridine for treating diseases of the central nervous and vascular systems
CN1084332C (zh) 含蝶呤衍生物的活性氧消除剂
HU211478A9 (en) Pharmaceutical composition and process for the preparation thereof
JPWO2012014805A1 (ja) 一酸化窒素生成調節剤
KR20110082564A (ko) 통상의 와파린 요법에 비해 효능이 향상된 다비가트란 에텍실레이트 또는 이의 염을 사용하여 혈전증을 치료하거나 예방하는 방법
CN102180832A (zh) 脑缺血保护用化合物及制备方法
ES2584403T3 (es) Procedimiento de elaboración de microcápsulas entéricas de alginato por gelación iónica que contienen diclofenac o una de sus sales y composición farmacéutica multiparticulada que las contiene
CA2354574C (fr) Troxerutine a forte teneur en trihydroxy-ethyl-rutoside et procede de preparation
BRPI0714786A2 (pt) antioxidante para tratamento e profilaxia de doenÇas associadas com a tensço oxodativa e a falta de oxigÊnio no corpo, processo de produÇço de um antioxodante, granulados para a produÇço de meio medicinal ou profilÁtico para tratamento e prevenÇço de doenÇas associadas com tensço oxidativa e falta de oxigÊnio no corpo, e preparaÇço na forma de tablete ou encapsulada para tratamento e prevenÇço de doenÇas associadas com tensço oxidativa e falta de oxigÊnio no corpo
EA015483B1 (ru) ПРИМЕНЕНИЕ ИНГИБИТОРА p38 КИНАЗЫ ДЛЯ ЛЕЧЕНИЯ ПСИХИАТРИЧЕСКИХ РАССТРОЙСТВ
KR20090100416A (ko) 탈모증의 예방 또는 치료제
CN112912084B (zh) 芸香苷组成物
HK1261881A1 (en) Phenol compound and combination of same with a benzodiazepine fused to 1,4-dihydropyridine for treating diseases of the central nervous and vascular systems
HK1261881B (en) Phenol compound and combination of same with a benzodiazepine fused to 1,4-dihydropyridine for treating diseases of the central nervous and vascular systems
RU2506950C2 (ru) Комбинация карбостирила и карнитина
TWI354672B (en) Antioxidants
HK40094968A (en) Methods of treating erythropoietic protoporphyria, x-linked protoporphyria, or congenital erythropoietic porphyria
HK40094968B (en) Methods of treating erythropoietic protoporphyria, x-linked protoporphyria, or congenital erythropoietic porphyria
HK40108227A (en) Methods of treating erythropoietic protoporphyria, x-linked protoporphyria, or congenital erythropoietic porphyria with glycine transport inhibitors
CN114853715A (zh) 一种有机亚硝酸根供体缩酮型前药及其制备方法与医药用途
BR112020000508B1 (pt) Composição orodispersível e uso de uma composição orodispersível

Legal Events

Date Code Title Description
B15V Prolongation of time limit allowed

Free format text: TENDO EM VISTA A PORTARIA INPI PR NO 120 DE 16/03/2020, PORTARIA INPI PR NO 161 DE 13/04/2020; PORTARIA INPI PR NO 166 DE 27/04/2020 E PORTARIA INPI PR NO 179 DE 11/05/2020, QUANTO A SUSPENSAO DOS PRAZOS VENCIDOS ENTRE 16/03/2020 A 31/05/2020, DEVOLVE-SE O PRAZO NESSE PEDIDO COM RELACAO A SOLICITACAO DO PEDIDO DE EXAME.

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 03/05/2017, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REF. RPI 2772 DE 20/02/2024 QUANTO AO TITULO.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 8A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2825 DE 25-02-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.